New shot could help chinese heart patients lower bad cholesterol
NCT ID NCT06941792
First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This study tests a drug called inclisiran in about 1,590 Chinese adults with coronary heart disease who still have high LDL (bad) cholesterol despite taking statins. Participants receive either inclisiran or standard care, and researchers check how much LDL drops over one year. The goal is to see if inclisiran works better in real-world settings to help control cholesterol and reduce heart risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigated Site
Taiyuan, Shanxi, 030000, China
-
Novartis Investigative Site
Anqing, Anhui, 246003, China
-
Novartis Investigative Site
Beijing, Beijing Municipality, 102218, China
-
Novartis Investigative Site
Chongqing, Chongqing Municipality, 400010, China
-
Novartis Investigative Site
Longyan, Fujian, 364099, China
-
Novartis Investigative Site
Jiamusi, Heilongjiang, 154002, China
-
Novartis Investigative Site
Zhengzhou, Henan, 451400, China
-
Novartis Investigative Site
Baotou, Inner Mongolia, 014010, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110016, China
-
Novartis Investigative Site
Shenyang, Liaoning, 121100, China
-
Novartis Investigative Site
Jining, Shandong, 272000, China
-
Novartis Investigative Site
Weifang, Shandong, 261000, China
-
Novartis Investigative Site
Shanghai, Shanghai Municipality, 200065, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610031, China
-
Novartis Investigative Site
Ürümqi, Xinjiang Uygur Autonomous Region, 830054, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310007, China
-
Novartis Investigative Site
Jinhua, Zhejiang, 321000, China
-
Novartis Investigative Site
Ningbo, Zhejiang, 315000, China
-
Novartis Investigative Site
Wenzhou, Zhejiang, 325000, China
Conditions
Explore the condition pages connected to this study.